TY - T1的纵向(<一口> 11 < /一口> C] (±) dihydrotetrabenazine宠物研究性别差异的多巴胺能的发展障碍的帕金森尾状(P6.064) JF -神经学乔-神经学六世- 82 - 10补充SP - P6.064盟Nandhagopal Ramachandiran AU -迈克尔·舒尔茨AU -丽莎Kuramoto盟杰奎琳·克拉格AU -维斯纳S首页ossi盟劳尔de la Fuente-Fernandez盟——Stoessl Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/P6.064.abstract N2 -目的:调查是否有差异的发展多巴胺功能障碍在尾状零星的帕金森病(PD)男人和女人之间。背景:帕金森病是一种临床异质性疾病,男性更常见。有一个缺乏信息发展的性别差异多巴胺功能障碍的帕金森尾状。设计/方法:PD科目(n = 78;58岁男性和20名女性)接受正电子发射断层扫描(PET)扫描使用c [11] (±) dihydrotetrabenazine (DTBZ),纹状体的多巴胺突触前标记估计密度水泡单胺转运蛋白2型。受试者扫描在初始后再次访问和4和8年的随访。非线性多元回归分析与随机效应,形成BPND (t) = a * e (-bt-dA) + c (BPND =组织输入导出绑定潜力;a, b, c, d是常量估计;t =症状持续时间;A =年龄出现症状)是利用模型DTBZ绑定的时间变化在严重影响尾两组(男性和女性)。 RESULTS: The study comprised a total of 156 DTBZ scans. Between the two groups, there were no statistically significant differences in either the loss of caudate DTBZ binding at symptom onset or the rate of decline in tracer binding over the entire 25 years of symptom duration. CONCLUSIONS: To the extent that DTBZ scan provides a reliable estimate of loss of dopamine terminal density, our findings suggest similar rates of progression of dopaminergic dysfunction in the parkinsonian caudate in men and women. Study Supported by: The Canadian Institutes of Health Research, the Michael Smith Foundation for Health Research and the Canada Research Chairs.Disclosure: Dr. Ramachandiran has nothing to disclose. Dr. Schulzer has nothing to disclose. Dr. Kuramoto has nothing to disclose. Dr. Cragg has nothing to disclose. Dr. Sossi has nothing to disclose. Dr. de la Fuente-Fernández has nothing to disclose. Dr. Stoessl has received personal compensation for activities with Teva Neuroscience, AbbVie, and UCB Pharma.Thursday, May 1 2014, 7:30 am-11:00 am ER -